Von Willebrand's Disease

Von Willebrand's Disease is the most prevalent inherited bleeding disorder affecting domestic dogs, caused by a quantitative deficiency or qualitative dysfunction of Von Willebrand factor (vWF). Von Willebrand factor is a large, multimeric glycoprotein produced by megakaryocytes and vascular endothelial cells that plays a critical role in primary hemostasis. Its primary function is to mediate the adhesion of platelets to exposed subendothelial collagen at sites of vascular injury, forming the initial platelet plug that is the first step in stopping bleeding.

The disease was named after the Finnish physician Erik Adolf von Willebrand, who first described the condition in humans in 1926. The canine form of the disease was subsequently identified and has since been recognized across more than fifty dog breeds, making it one of the most widespread genetic disorders in the canine population. The disease follows an autosomal inheritance pattern, meaning that both males and females are equally affected, distinguishing it from hemophilia, which is X-linked and predominantly affects males.

Von Willebrand factor also serves as a carrier protein for coagulation Factor VIII in the bloodstream, protecting it from premature degradation. When vWF levels are significantly reduced, Factor VIII levels may also decrease, compounding the bleeding tendency. This dual role of vWF in both platelet adhesion and Factor VIII stabilization explains why severe forms of vWD can result in both primary hemostatic defects (prolonged bleeding from mucosal surfaces) and secondary coagulation abnormalities.

The clinical significance of vWD varies enormously depending on the type and severity of the disease. Many dogs carry the genetic mutation and have reduced vWF levels but never experience clinically significant bleeding episodes during their lifetime. Others, particularly those with severe forms of the disease, may present with life-threatening hemorrhage following surgery, trauma, or even spontaneously. Understanding the different types and their breed associations is essential for proper risk assessment and management.

Von Willebrand's Disease in dogs is classified into three distinct types based on the quantity and structural characteristics of the Von Willebrand factor present in the blood. Each type has different genetic underpinnings, breed associations, and clinical severity profiles. Accurate classification is important because the type of vWD directly influences the prognosis and management approach.

Type 1 vWD is by far the most common form, accounting for the vast majority of diagnosed cases. It is characterized by a proportional decrease in all vWF multimer sizes, meaning the protein is structurally normal but present in reduced quantities. Type 1 vWD is inherited as an autosomal trait with incomplete penetrance, meaning that dogs carrying the mutation may have vWF levels ranging from mildly reduced to moderately deficient. Most dogs with Type 1 vWD have mild to moderate bleeding tendencies, and many remain asymptomatic throughout their lives unless subjected to significant surgical or traumatic challenges. The Doberman Pinscher is the breed most strongly associated with Type 1 vWD, with prevalence estimates in some populations exceeding sixty percent.

Type 2 vWD is a qualitative defect characterized by a disproportionate decrease in the large and intermediate multimers of vWF, which are the most hemostatically active forms. Because the high-molecular-weight multimers are the forms most effective at binding platelets to damaged vessel walls, their absence results in a more severe bleeding phenotype than would be predicted by the total vWF concentration alone. Type 2 vWD is most commonly identified in German Shorthaired Pointers and German Wirehaired Pointers, and it is inherited as an autosomal recessive trait. Dogs homozygous for the Type 2 mutation typically have a moderate to severe bleeding tendency.

Type 3 vWD is the most severe form, characterized by a virtually complete absence of Von Willebrand factor in the blood. This form is inherited as an autosomal recessive trait, and affected dogs have a severe bleeding diathesis that can be life-threatening. Type 3 vWD has been identified in several breeds, including the Scottish Terrier, Chesapeake Bay Retriever, Shetland Sheepdog, and Dutch Kooikerhondje. Dogs with Type 3 vWD may experience spontaneous bleeding episodes, severe hemorrhage from minor injuries, and are at extreme risk during any surgical procedure.

Von Willebrand's Disease is caused by mutations in the VWF gene, which encodes the Von Willebrand factor protein. The VWF gene is located on an autosome (not a sex chromosome), which means the disease affects males and females equally. Different mutations in the VWF gene are responsible for the different types of vWD, and in many cases, the specific causative mutation has been identified at the molecular level, enabling the development of breed-specific DNA tests.

For Type 1 vWD, the inheritance pattern is autosomal with variable expressivity and incomplete penetrance. This means that dogs carrying even a single copy of the mutation may show reduced vWF levels, though the degree of reduction and the clinical significance vary widely among individuals. In Doberman Pinschers, the most commonly identified mutation is a single nucleotide polymorphism in the VWF gene that affects protein expression levels. Environmental factors, concurrent illnesses, hormonal status, and stress can all influence vWF levels in dogs carrying the Type 1 mutation, contributing to the variability in clinical presentation.

Type 2 vWD results from mutations that alter the structure of the vWF protein, specifically disrupting the ability of the molecule to form the large multimeric complexes needed for effective platelet adhesion. The mutation identified in German Shorthaired Pointers affects a region of the protein involved in multimer assembly, leading to the selective loss of the high-molecular-weight multimers. Carriers of one copy of the Type 2 mutation generally have normal hemostasis, while dogs inheriting two copies (homozygotes) manifest clinical disease.

Type 3 vWD is caused by mutations that result in essentially no functional vWF production. These are typically null mutations, including large deletions, frameshift mutations, or premature stop codons that prevent the production of any functional protein. The autosomal recessive inheritance means that both parents must carry at least one copy of the mutation for affected offspring to be produced. Carrier dogs (heterozygotes) typically have vWF levels approximately half of normal but are clinically unaffected. The identification of specific mutations for each breed has made DNA-based carrier testing widely available, which is a powerful tool for reducing disease prevalence through informed breeding decisions.

The clinical signs of Von Willebrand's Disease reflect impaired primary hemostasis and vary widely in severity depending on the type of vWD and the individual dog's vWF levels. Many dogs with mild forms of the disease, particularly those with Type 1 vWD and only moderately reduced vWF levels, may go their entire lives without any noticeable bleeding problems. The disease often becomes apparent only when the dog undergoes surgery, experiences trauma, or is subjected to other hemostatic challenges.

The most characteristic signs of vWD involve prolonged or excessive bleeding from mucosal surfaces. Owners may notice spontaneous nosebleeds (epistaxis), bleeding from the gums, blood in the urine (hematuria), blood in the stool (melena or hematochezia), or prolonged bleeding from the gingiva during teething in puppies. Female dogs with vWD may experience excessive bleeding during estrus cycles or following whelping. These mucosal surface bleeds reflect the role of vWF in platelet adhesion at sites where blood vessels are close to the surface.

Excessive bleeding during or after surgical procedures is a hallmark of vWD and may be the first indication that a dog has the condition. Routine procedures such as spaying, neutering, dewclaw removal, ear cropping, or dental extractions can result in prolonged hemorrhage that is disproportionate to the degree of surgical trauma. Post-surgical bleeding may continue for hours to days and can require blood transfusions or other interventions to control. Nail trimming that accidentally cuts the quick may result in bleeding that is unusually difficult to stop.

In dogs with Type 3 vWD or severe Type 2 vWD, spontaneous bleeding episodes can occur without any identifiable trigger. These may include spontaneous joint hemorrhage (hemarthrosis), intramuscular bleeding that causes lameness and swelling, subcutaneous hematoma formation, and in severe cases, internal hemorrhage that can be life-threatening. Puppies with severe vWD may present with excessive bruising, prolonged bleeding from the umbilical cord at birth, or hemorrhage from sites of routine vaccinations. The severity and frequency of bleeding episodes tend to be somewhat unpredictable, with periods of relative stability interspersed with acute hemorrhagic crises.

The diagnosis of Von Willebrand's Disease involves a combination of clinical assessment, screening coagulation tests, specific vWF assays, and genetic testing. A thorough clinical history is the starting point, with particular attention to any episodes of excessive or prolonged bleeding, a family history of bleeding tendencies, and breed predisposition. Physical examination findings are often unremarkable in dogs that are not actively bleeding, though petechiae or ecchymoses may be noted in more severely affected individuals.

Screening coagulation tests provide initial information about hemostatic function but are not specific for vWD. The buccal mucosal bleeding time (BMBT) is a simple in-clinic test that evaluates primary hemostasis by measuring the time required for a standardized incision on the inner lip to stop bleeding. A prolonged BMBT is suggestive of a platelet function or number disorder, including vWD, but is not specific. Standard coagulation tests such as prothrombin time (PT) and activated partial thromboplastin time (aPTT) are typically normal in dogs with vWD unless the disease is severe enough to secondarily reduce Factor VIII levels.

The definitive laboratory test for vWD is measurement of Von Willebrand factor antigen concentration (vWF:Ag) in plasma, typically performed using an enzyme-linked immunosorbent assay (ELISA). Results are reported as a percentage of normal, with reference ranges established for each laboratory. Generally, vWF:Ag levels above 70 percent are considered normal, levels between 50 and 70 percent are borderline, and levels below 50 percent indicate vWD. Dogs with Type 3 vWD typically have vWF:Ag levels below one percent. It is important to note that vWF levels can fluctuate based on physiological conditions, stress, age, reproductive status, and concurrent illness, so a single borderline result should be interpreted with caution and potentially repeated.

DNA testing for specific vWD mutations is now available for many breeds and represents the gold standard for identifying carriers and affected dogs. Unlike vWF:Ag measurement, which can fluctuate, DNA test results are definitive and do not change over the dog's lifetime. Genetic testing can be performed on a blood sample or cheek swab at any age, including in young puppies, making it an invaluable tool for breeders. Breed-specific tests are available for the mutations causing Type 1 vWD in Doberman Pinschers and numerous other breeds, Type 2 vWD in German Shorthaired and Wirehaired Pointers, and Type 3 vWD in Scottish Terriers, Shetland Sheepdogs, and several other breeds.

There is no cure for Von Willebrand's Disease, and management is focused on preventing bleeding episodes, preparing for hemostatic challenges, and treating acute hemorrhage when it occurs. The approach to management varies significantly depending on the type and severity of the disease. Dogs with mild Type 1 vWD may require little to no ongoing treatment, while dogs with Type 3 vWD require careful lifelong management and emergency preparedness.

For planned surgical procedures, preoperative preparation is essential for dogs with known or suspected vWD. Desmopressin (DDAVP, 1-deamino-8-D-arginine vasopressin) is a synthetic vasopressin analogue that can temporarily increase vWF release from endothelial cell storage sites. Administered intravenously or subcutaneously approximately 30 minutes before surgery, DDAVP can transiently raise vWF levels and improve hemostasis in dogs with Type 1 vWD. However, DDAVP is generally ineffective in Type 2 and Type 3 vWD because the underlying problem in Type 2 is structural, and in Type 3 there are no vWF stores to release.

When acute hemorrhage occurs or when dogs with moderate to severe vWD require surgical intervention, transfusion therapy is the primary treatment. Fresh frozen plasma (FFP) or cryoprecipitate are the blood products of choice because they contain functional vWF along with other coagulation factors. Cryoprecipitate is the preferred product when available because it provides a concentrated source of vWF, Factor VIII, and fibrinogen in a smaller volume than FFP, reducing the risk of volume overload. Fresh whole blood transfusion may be necessary if the dog has concurrent significant blood loss and requires both red blood cell replacement and coagulation factor supplementation.

Day-to-day management of dogs with vWD centers on injury prevention and awareness. Owners should avoid activities that carry a high risk of trauma, keep nails trimmed carefully to avoid cutting the quick, ensure the dog's environment is free from sharp objects, and inform all veterinary professionals involved in the dog's care about the vWD diagnosis. Medical identification tags or notes in the dog's medical record should clearly indicate the diagnosis and type of vWD. Medications that impair platelet function, including nonsteroidal anti-inflammatory drugs (NSAIDs) and aspirin, should be strictly avoided in dogs with vWD.

Von Willebrand's Disease has been identified in over fifty breeds, but the prevalence, type, and clinical significance vary dramatically across the canine population. The Doberman Pinscher has historically had the highest carrier rate for vWD of any breed, with studies estimating that more than sixty percent of Dobermans carry at least one copy of the Type 1 vWD mutation. However, the majority of affected Dobermans have only moderately reduced vWF levels and experience mild bleeding tendencies, with clinically significant hemorrhage occurring primarily during surgical procedures.

German Shorthaired Pointers and German Wirehaired Pointers are the breeds primarily associated with Type 2 vWD. Because Type 2 involves a qualitative defect with loss of the most hemostatically active vWF multimers, affected dogs in these breeds tend to have more severe clinical bleeding than would be expected based on their total vWF antigen levels. Breeders of these pointing breeds should use DNA testing to identify carriers and plan matings that avoid producing homozygous affected offspring.

Several breeds are known to carry Type 3 vWD mutations, including the Scottish Terrier, Chesapeake Bay Retriever, Shetland Sheepdog, and Dutch Kooikerhondje. Type 3 is the most clinically severe form, and affected dogs are at significant risk for life-threatening hemorrhage. The Scottish Terrier population has been particularly well studied, and the carrier frequency in some populations has been high enough to warrant routine genetic screening of all breeding animals. DNA testing programs in these breeds have been instrumental in reducing the incidence of affected puppies.

Beyond these primary breed associations, numerous other breeds have documented vWD prevalence. The Pembroke Welsh Corgi, Manchester Terrier, Standard Poodle, Miniature Schnauzer, Golden Retriever, Bernese Mountain Dog, and Papillon are among the many breeds with known carrier populations. Mixed-breed dogs with significant genetic contributions from affected breeds can also carry vWD mutations. The wide availability of breed-specific DNA tests has empowered breeders to make informed decisions, and widespread testing programs have begun to reduce carrier frequencies in several breeds over recent decades.

Owners of dogs with moderate to severe Von Willebrand's Disease should maintain a comprehensive emergency plan to address acute bleeding episodes. Knowing the location and contact information for the nearest emergency veterinary hospital with blood banking and transfusion capabilities is essential, as community veterinary practices may not have the blood products or expertise needed to manage acute hemorrhage in vWD patients. Some owners of dogs with severe vWD choose to bank their dog's blood type information and cross-match results in advance to expedite transfusion if needed.

First aid measures for minor bleeding episodes include applying direct pressure with clean gauze or cloth for a minimum of five to ten minutes without removing the bandage to check. Cold compresses can be applied to reduce blood flow to the area. Topical hemostatic agents, including styptic powder for nail bleeds, can be kept on hand. However, any bleeding that does not stop with direct pressure within ten to fifteen minutes, or any bleeding that is profuse or involves a large area, warrants immediate veterinary attention.

At the veterinary hospital, treatment of acute hemorrhage typically involves transfusion of cryoprecipitate or fresh frozen plasma to replace the missing vWF. The volume and frequency of transfusion depend on the severity of bleeding and the dog's clinical status. In life-threatening hemorrhage, fresh whole blood may be administered to simultaneously replace red blood cells and provide coagulation factors. Aminocaproic acid or tranexamic acid, which are antifibrinolytic agents that help stabilize formed clots, may be administered as adjunctive therapy to reduce the breakdown of clots at the bleeding site.

Post-bleeding episode monitoring is important because rebleeding can occur once the transfused vWF is consumed or cleared from the circulation. Dogs should be kept quiet and confined for several days following a significant bleeding episode, with activity restricted to prevent disruption of healing blood clots. Follow-up hematocrit and total protein measurements should be performed to ensure that the dog has stabilized and is not experiencing ongoing occult blood loss. Owners should monitor for signs of recurring hemorrhage, including pale gums, lethargy, weakness, collapse, or visible blood in urine, stool, or from wound sites.

The availability of DNA-based genetic tests for Von Willebrand's Disease has transformed the ability of breeders to reduce the prevalence of this condition in affected breeds. Unlike phenotypic tests that measure vWF antigen levels and can fluctuate with physiological conditions, DNA tests provide a definitive, one-time determination of a dog's genetic status as clear (no mutation copies), carrier (one mutation copy), or affected (two mutation copies). This clarity enables breeders to make fully informed mating decisions.

The recommended breeding strategy for vWD follows the principles used for any autosomal recessive or autosomal trait with incomplete dominance. Ideally, clear dogs should be bred to clear dogs, which guarantees that no offspring will be carriers or affected. When the carrier frequency in a breed is very high, immediately eliminating all carriers from the breeding pool could drastically reduce genetic diversity, which carries its own health risks. In such cases, a more gradual approach involves breeding carriers only to clear dogs, which produces no affected offspring while maintaining genetic diversity, and then progressively selecting clear offspring for future breeding.

Genetic testing should be performed on all breeding animals in predisposed breeds, and ideally before the dog reaches breeding age. Test results should be recorded with breed registries and health databases to facilitate transparency and informed breeding decisions across the breed community. Several breed clubs and kennel clubs have incorporated vWD testing into their recommended or required health screening protocols. Puppy buyers purchasing from predisposed breeds should request proof of vWD genetic testing for both parents.

The impact of genetic testing programs on vWD prevalence has been demonstrably positive in several breeds. In populations where testing has been widely adopted and breeding recommendations followed, the frequency of affected dogs has decreased significantly over time. However, the effectiveness of these programs depends on broad participation within the breed community, accurate reporting of results, and adherence to breeding guidelines. Continued education of breeders and puppy buyers about the importance of genetic testing remains a priority for breed health organizations.

The prognosis for dogs with Von Willebrand's Disease varies significantly depending on the type and severity of the condition. Dogs with mild Type 1 vWD, which constitutes the majority of diagnosed cases, generally have an excellent prognosis and a normal life expectancy. Many of these dogs live their entire lives without experiencing a significant bleeding episode, particularly if their owners and veterinarians are aware of the diagnosis and take appropriate precautions during surgical procedures or in the event of trauma.

Dogs with moderate vWD, whether Type 1 with significantly reduced vWF levels or Type 2, have a good prognosis with appropriate management but face a higher risk of bleeding complications during their lifetime. These dogs can live full, active lives with proper precautions, but their owners must remain vigilant about injury prevention, medication avoidance, and surgical preparation. Having an established relationship with a veterinary team experienced in managing coagulopathies and with access to blood products is important for these patients.

The prognosis for dogs with Type 3 vWD is more guarded due to the potential for severe, life-threatening bleeding episodes. However, with diligent owner management, careful veterinary oversight, and prompt access to emergency transfusion services, many dogs with Type 3 vWD can live for years with a good quality of life. The key factors in determining outcome for these dogs are the owner's preparedness, the accessibility of emergency veterinary care, and the speed with which acute bleeding episodes are recognized and treated.

Quality of life for dogs with vWD is generally good to excellent for all but the most severely affected individuals. The condition does not cause chronic pain or progressive organ damage between bleeding episodes, and dogs can engage in normal activities with reasonable precautions. The psychological impact on owners should not be underestimated, however, as living with a dog that has a potentially life-threatening bleeding disorder can be a source of ongoing anxiety. Education, preparedness planning, and a strong relationship with a knowledgeable veterinary team can help alleviate owner concerns and ensure that both the dog and the family enjoy a positive quality of life together.